摘要
目的探讨癌胚抗原(CEA)在厄洛替尼治疗表皮生长因子受体(EGFR)突变的晚期非小细胞肺癌(NSCLC)患者中的意义。方法对EGFR突变的晚期NSCLC 78例患者,依CEA的检测结果将患者分为CEA阳性组和CEA阴性组,每天口服150mg厄洛替尼直至疾病进展,并对两组患者的疗效进行评价。结果血清CEA阳性组患者的有效率(χ2=4.495,P=0.033)和疾病控制率(χ2=5.028 2,P=0.024 8)均高于CEA阴性组,而且无进展生存时间也比CEA阴性组长(χ2=9.826,P=0.002)。结论血清CEA水平能够反映EGFR突变的晚期NSCLC患者的疗效及预后。
Objective To explore the significance of carcinoebryonic antigen（CEA）in patients of advanced non-small cell lung cancer（NSCLC） with epidermal growth factor receptor（EGFR） mutations treated by erlotinib.Methods 78 advanced NSCLC patients with EGFR mutations were divided into CEA positive group and CEA negative group,who had been received 150 mg oral doses of erlotinib once daily until disease progression and evaluated the response.Results The response rate（χ2=4.495,P=0.033）and the disease controlled rate（χ2=5.028 2,P=0.024 8） of erlotinib in CEA positive group were significantly difference higher than those in CEA negative group,and the median progression-free survival time（χ2=9.826,P=0.002）was also longer than the that in CEA negative group.Conclusion It was reflected the curative effect and prognosis of advanced NSCLC patients with EGFR mutations for the level of serum CEA.
出处
《重庆医学》
CAS
CSCD
北大核心
2013年第3期279-280,共2页
Chongqing medicine
关键词
癌胚抗原
癌
非小细胞肺
厄洛替尼
carcinoebryonic antigen
carcinoma
non-small cell lung
erlotinib
